Moxi laser Before and After: What Results Look Like

Sciton describes MOXI as a non-ablative fractional laser built around the 1927 nm wavelength, which targets water in the skin rather than pigment, and positions it for “prejuvenation”, early sun damage and uneven tone and texture.

The Moxi laser guide covers how the treatment works and what a session involves; this page is about what changes in the skin.

What Sciton's 1927 nm system is cleared for is narrower than the marketing.

That system, the JOULE 1927nm Laser System, was 510(k)-cleared on March 6, 2019 (K182173) for dermatological procedures requiring coagulation of soft tissue, treatment of actinic keratosis, and treatment of benign pigmented lesions such as age spots, sun spots and freckles. “Prejuvenation” and “glow” are marketing terms, not cleared indications — and we did not find a MOXI-specific 510(k) summary, so we cannot tell you which clearance covers MOXI as sold today.

The independent evidence sits one step away from MOXI, on the same wavelength.

A 2020 review of 1440/1927 nm non-ablative fractional diode lasers — a Solta Clear + Brilliant-type system, not MOXI — reported improvements in tone, texture, fine lines and dyschromia, with transient side effects and minimal downtime, and called 1927 nm appropriate for skin of color with reduced adverse-event risk compared with other fractional lasers.

A 2025 review of that laser class found the expected reactions (redness, swelling, crusting) were mild to moderate and self-limited, with no serious adverse events reported in patients with skin of color.

Sciton's own answer is that MOXI can produce evenly toned, radiant skin “in as little as a single treatment—although 2-4 are recommended”.

That is the manufacturer's recommendation, and it is the only session-count guidance in the record we reviewed: we did not find an independent study measuring what MOXI changes after one session versus two, three or four.

The one-treatment question deserves its own caution.

For anyone weighing a “Moxi laser before and after 1 treatment” photo: the only before-and-after figure on this page, a mean 43% improvement in post-inflammatory hyperpigmentation, came from a course of at least 2 sessions on a different device.

A single-session gallery, like any before-and-after photo, is one person's outcome under one practice's conditions, and it is fair to ask how it compares with that practice's typical multi-session result.

Here is the concern-by-concern record, with each row's scope kept exactly as the source states it.

Rows that name a device other than MOXI reflect the study, not a typo: no MOXI-specific results by concern were found in the sources we reviewed.

Two gaps sit next to the table.

We found no MOXI-specific study reporting results for any concern, and no source that measures how Moxi outcomes differ by concern severity or skin type.

If a gallery shows you a concern this table does not cover, the honest question to ask is what evidence stands behind it.

Session count is the first variable, and the record addresses it directly: Sciton says results can come from a single treatment while recommending 2 to 4, and the 43% pigment figure came from a course of at least 2 sessions.

Skin type is the second.

Sciton says MOXI treats all skin types year-round because the 1927 nm wavelength targets water rather than pigment — the manufacturer's claim, not an established fact.

The independent evidence is wavelength-level: the 2020 review called 1927 nm appropriate for skin of color with reduced adverse-event risk versus other fractional lasers, and the 61-patient pigment study measured Fitzpatrick IV–VI skin specifically.

The third variable is the evidence itself.

The outcome figures on this page come from studies of 1927 nm lasers other than MOXI, the pigment review came from a single center, and we found no source quantifying how MOXI results differ by age, sex or skin type. “Results vary” is not a disclaimer here — it is what the record shows, and it is why no photo can tell you your result.

Photos in a provider's marketing are claims, not documentation.

Under the FTC Endorsement Guides (16 CFR 255.2), an ad featuring one consumer's result is likely to be read as representing typical results; if the advertiser lacks substantiation that the result is representative, the FTC says the ad should clearly and conspicuously disclose the generally expected performance.

The FTC's own example: a before-and-after picture paired with a results claim conveys that the result is typical, and the ad would be deceptive if consumers cannot generally expect that result.

A “results not typical” disclaimer is not reassurance — FTC research found those disclaimers ineffective.

The useful move in a consultation is to ask for the generally expected result in words: for your concern, your skin type and the number of sessions planned, not for the one face in the frame.

Photos are also patient data.

Under HIPAA, a covered provider must obtain a patient's written authorization before using protected health information for marketing (45 CFR 164.508(a)(3)), and full-face photographic images are listed identifiers of protected health information (45 CFR 164.514(b)(2)).

Whether a given med spa counts as a HIPAA covered entity depends on factors such as whether it conducts standard electronic transactions like insurance billing — so it is reasonable to ask how a photo you are shown was cleared for use.